<DOC>
	<DOCNO>NCT00224029</DOCNO>
	<brief_summary>This study evaluate efficacy safety anticholinergic drug treatment administer transdermal patch treat overactive bladder adult spinal cord injury .</brief_summary>
	<brief_title>A Study Evaluating Oxybutynin Patients With Neurogenic Overactive Bladder Associated With Neurological Condition</brief_title>
	<detailed_description>The Dose Titration Period begin 3.9 mg/day 7.8 mg/day start dose completion 3-day diary baseline evaluation , include urodynamic testing . The clean intermittent catheterization ( CIC ) frequency remain constant throughout Dose Titration Period . The dose adjust every two week Dose Titration Period increase one dose level , investigator 's discretion , base patient 's symptom . If patient achieve complete continence report tolerable absence side effect , patient continue dose duration 8-week Titration Period . If patient report unacceptable side effect , dose reduce one level . This reduce dose consider maximum tolerable dose patient patient continue dose duration 8-week Titration Period . The dose level evaluate 3.9 mg/day , 7.8 mg/day , 9.1 mg/day , 11.7 mg/day . Of 22 subject modify intent-to-treat population evaluate efficacy , 0 3.9 mg/day dose group , 3 7.8 mg/day dose group , 8 9.1 mg/day dose group , 11 11.7 mg/day dose group .</detailed_description>
	<mesh_term>Reflex , Abnormal</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>At least 18 year age day consent ; Is male , nonpregnant nonlactating female either nonchildbearing potential , use adequate mean birth control ; Has h/o urinary incontinence neurogenic bladder spinal cord injury etiology ; Has impairment base American Spinal Injury Association ( ASIA ) ; Use clean intermittent catheterization ; Has urinary incontinence schedule catheterization ; Capable understand comply protocol . Have one treatable condition , neurogenic bladder dysfunction , may cause urinary incontinence urgency ; Have medical condition precludes participation study , may confound outcome study ; History major low urinary tract surgery , procedure ; Has active skin disorder , affect TDS application site area ; Hypersensitivity investigational drug ; Has participate study involve administration investigational compound within 30 day study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>